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Objectives: To evaluate characteristics and outcomes of patients presenting with
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acute myocardial infarction and cardiogenic shock (AMICS) during the coronavirus
disease 2019 (COVID‐19) pandemic.
Background: The COVID‐19 pandemic has created challenges in delivering acute
cardiovascular care. Quality measures and outcomes of patients presenting with
AMICS during COVID‐19 in the United States have not been well described.
Methods: We identified 406 patients from the National Cardiogenic Shock Initiative
(NCSI) with AMICS and divided them into those presenting before (N = 346, 5/9/
2016−2/29/2020) and those presenting during the COVID‐19 pandemic (N = 60, 3/
1/2020−11/10/2020). We compared baseline clinical data, admission character-
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istics, and outcomes.
Results: The median age of the cohort was 64 years, and 23.7% of the group was
female. There were no significant differences in age, sex, and medical comorbidities
between the two groups. Patients presenting during the pandemic were less likely to
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be Black compared to those presenting prior. Median door to balloon (90 vs. 88 min,
p = 0.38), door to support (88 vs. 78 min, p = 0.13), and the onset of shock to support
(74 vs. 62 min, p = 0.15) times were not significantly different between the two
groups. Patients presented with ST‐elevation myocardial infarction more often
during the COVID‐19 period (95.0% vs. 80.0%, p = 0.005). In adjusted logistic
regression models, COVID‐19 period did not significantly associate with survival to
discharge (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.54−2.19, p = 0.81) or
with 1‐month survival (OR 0.82, 95% CI 0.42−1.61, p = 0.56).
Conclusions: Care of patients presenting with AMICS has remained robust among
hospitals participating in the NCSI during the COVID‐19 pandemic.
KEYWORDS

acute myocardial infarction/STEMI; coronary artery disease, intervention; mechanical
circulatory support, ECMO/IABP/tandem/Impella; shock, cardiogenic

Abbreviations: ACS, acute coronary syndrome; AMICS, acute myocardial infarction and cardiogenic shock; COVID‐19, coronavirus disease 2019; NCSI, National Cardiogenic Shock Initiative;
PCI, percutaneous coronary intervention; STEMI, ST‐elevation myocardial infarction.
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The coronavirus disease 2019 (COVID‐19) pandemic has created
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METHODS
Study population

challenges in the delivery of acute cardiovascular care. Cohorts in
the United States1–4 and internationally5–10 have reported

The National Cardiogenic Shock Initiative (NCSI) is a prospective, single‐

decreases in hospital presentations of acute coronary syndrome

arm study assessing the impact of early mechanical circulatory support in

during the pandemic. Some studies have found worse outcomes

patients presenting with AMICS who were treated with PCI. Data leading

for patients with acute coronary syndrome presenting during

to the NCSI creation and enrollment details have been previously

COVID‐19,2,11–14 which may be related to hospital processes. An

described.18,19 Briefly, the NCSI included patients presenting with AMICS

English cohort, for example, found decreases in primary per-

for which a physician activated the catheterization laboratory. For

cutaneous coronary intervention (PCI) for ST‐elevation myocar-

patients with a left ventricular end diastolic pressure greater than

dial infarction (STEMI) and delays in both symptom‐to‐hospital

15 mmHg or a Cardiac Index less than 2.2 L/min/m2, the interventional

and door‐to‐balloon times.
reported in China.

11

Similar findings have also been

12,13

cardiologist placed an Impella, a powerful transcatheter axial flow pump
able to supply 2.5−4.0 L/min of forward systemic blood flow (Abiomed).

Patients presenting with acute myocardial infarction and

After placement of mechanical support, coronary angiography and PCI

cardiogenic shock (AMICS) have been reported to experience >30%

were performed. In the catheterization laboratory, calculations of cardiac

in‐hospital mortality.15–18 Given the significant morbidity and

power output and pulmonary artery pulsatility index were used to guide

mortality associated with AMICS, and the major disruptions to the

escalation or de‐escalation of pharmacologic and mechanical hemo-

delivery of acute cardiovascular care during the pandemic, it is

dynamic support at thresholds of 0.6 W and 0.9, respectively. The final

essential to understand AMICS diagnostic and outcome patterns

study cohort consisted of 406 patients enrolled between May 9, 2016,

during COVID‐19. Here, we analyze the clinical characteristics and

and November 10, 2020, from 80 hospitals across the United States.

outcomes of patients presenting with AMICS during COVID‐19 and

Our study divided the NCSI cohort into pre‐COVID‐19 (5/9/

compare them to those of patients presenting before the COVID‐19

2016−2/29/2020) and during COVID‐19 periods (3/1/2020−11/10/

pandemic.

2020) (Figure 1). We then compared baseline clinical characteristics,

F I G U R E 1 Central Illustration. Acute myocardial infarction and cardiogenic shock (AMICS) during COVID‐19. Presenting during the COVID‐19
pandemic did not decrease the risk of survival to discharge or 1 month for patients presenting with AMICS among medical centers participating in
the National Cardiogenic Shock Initiative from May 2016 to November 2020. Important quality metrics such as median door to balloon time, door
to support time, and the onset of shock to support also did not significantly differ compared during the COVID‐19 pandemic to prior. [Color figure
can be viewed at wileyonlinelibrary.com]
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admission features, and survival outcomes. We selected 3/1/2020 as

respectively. To further evaluate the impact of presentation period

the cutoff between periods as there were few COVID‐19 cases in the

on AMICS outcomes, logistic regression models were used. Models

United States before this date. As a sensitivity analysis, we repeated

were adjusted for demographics (age, sex, race) and baseline medical

comparisons of patient characteristics and outcomes using an earlier

history status (diabetes mellitus, transient ischemic attack/cerebro-

COVID‐19 period, set at the time of the first diagnosis of COVID‐19

vascular accident, end‐stage renal disease, chronic kidney disease,

within the United States. In this analysis, we compared patients

left ventricular ejection fraction <50%, prior coronary artery bypass

presenting between 5/9/2016 and 1/19/2020 to those presenting

grafting, prior PCI, prior myocardial infarction). Race was denoted as

between 1/20/2020 and 11/10/2020.

other if missing. The two‐sided level of significance was set to

Weekly decreases in AMICS presentations were calculated by
comparing the number of AMICS presentations recorded in NCSI

p < 0.05. All statistical analyses were performed using Stata version
15.1 (Stata Corp LLC).

from March 1, 2020, to November 10, 2020, with March 1, 2019, to
November 10, 2019. Each participating hospital enrolled patients
ethically and in a manner approved by their associated Institutional

3 |

RESULTS
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Review Board as previously reported.

Three hundred and forty‐six patients presented pre‐COVID‐19, and
60 patients presented during COVID‐19 (Table 1). The median age of

2.2

| Statistical analysis

the cohort was 64 years, and 23.7% of the group was female. There
were no significant differences in age, sex, and captured cardiovas-

Patients were divided into groups based on time of presentation

cular medical comorbidities between the two groups. Patients

(pre‐COVID‐19 vs. during COVID‐19). Demographics, baseline

presenting during the pandemic were less likely to be of the Black

medical comorbidities, admission characteristics, and quality metrics,

race (3.3% vs. 9.3%), and more likely to be of Hispanic (13.3% vs.

including hospital timings, were compared between the two groups

5.8%) and White race (76.7% vs. 66.8%) than patients presenting

using Kruskal−Wallis and χ for continuous and categorical variables,

before the COVID‐19 pandemic (p = 0.011; Table 1). Rates of

2

TABLE 1

Demographics and medical comorbidities of patients enrolled in NCSI stratified by coronavirus disease 2019 period

Period

Overall, N = 406
5/9/16−11/10/20

Before COVID‐19, N = 346
5/9/16−2/29/20

During COVID‐19, N = 60
3/1/20−11/10/20

p Value

Demographics
Age, years

64 (55−72)

64 (55−73)

65 (55−71)

0.99

Female, n (%)

96 (23.7)

84 (24.3)

12 (20)

0.47

Race, n (%)

0.011

Black

34 (8.4)

32 (9.3)

2 (3.3)

Hispanic

28 (6.9)

20 (5.8)

8 (13.3)

277 (68.2)

231 (66.8)

46 (76.7)

67 (16.5)

63 (18.2)

4 (6.7)

160 (40.4)

133 (39.5)

27 (45.8)

0.36

Prior history of TIA/CVA, n (%)

37 (9.4)

33 (9.9)

4 (6.7)

0.44

End‐stage renal disease, n (%)

15 (3.8)

14 (4.1)

1 (1.7)

0.36

Chronic kidney disease, n (%)

50 (12.6)

40 (11.9)

10 (16.7)

0.30

Prior LVEF < 50%, n (%)

88 (23.1)

78 (24.1)

10 (17.5)

0.28

Prior CABG, n (%)

24 (6.0)

21 (6.2)

3 (5.0)

0.72

Prior PCI, n (%)

97 (24.5)

81 (24.1)

16 (26.7)

0.67

Prior MI, n (%)

79 (20.0)

66 (19.7)

13 (21.7)

0.73

White
Other/not available
Medical comorbidities
Diabetes mellitus, n (%)

Note: Continuous variables are presented as median (25th−75th percentile). Categorical variables are presented as n (%). Continuous and categorical
variables were compared using Kruskal−Wallis and χ2 tests, respectively.
Abbreviations: CABG, coronary artery bypass grafting; COVID‐19, coronavirus disease‐2019; CVA, cerebrovascular accident; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; n, frequency; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; %, percentage.

1522726x, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ccd.30390 by Henry Ford Health System, Wiley Online Library on [11/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

570

|

ET AL.

TABLE 2

571

Admission characteristics, hospital times, and outcomes of patients enrolled in NCSI stratified by coronavirus disease 2019 period

Period

Overall, N = 406
5/9/16−11/10/20

Before COVID‐19,
N = 346
5/9/16−2/29/20

During COVID‐19,
N = 60
3/1/20−11/10/20

p Value

Admission characteristics
Transferred from another hospital, n (%)

106 (26.1)

96 (27.8)

10 (16.7)

0.07

Cardiac arrest in‐hospital before arrival to cath lab, n (%)

118 (29.1)

100 (28.9)

18 (30.0)

0.86

Cardiac arrest out of hospital before arrival to cath lab, n (%)

68 (16.8)

58 (16.8)

10 (16.7)

0.98

Treated with hypothermia, n (%)

39 (11.0)

34 (11.5)

5 (8.5)

0.5

Lactate pre‐Impella, mmol/L

3.4 (2.0–6.2)

3.7 (2.0–6.7)

2.5 (2.0–5.1)

0.17

Shock on admission, n (%)

270 (66.7)

234 (67.8)

36 (60.0)

0.24

STEMI, n (%)

333 (82.2)

276 (80.0)

57 (95.0)

0.005

Hospital times
Door to balloon time, min

89 (60−137)

90 (58−146)

88 (67−108)

0.38

Door to support time, min

87 (58−156)

88 (58−159)

78 (59−111)

0.13

Onset of shock to support time, min

71 (31−116)

74 (34−119)

62 (27−98)

0.15

Outcomes
Index procedure survival, n (%)

400 (98.5)

341 (98.6)

59 (98.3)

0.9

Survival to discharge, n (%)

287 (70.7)

243 (70.2)

44 (73.3)

0.63

One‐month survival, n (%)

272 (68.2)

232 (68.2)

40 (67.8)

0.95

Note: Continuous variables are presented as median (25th−75th percentile). Categorical variables are presented as n (%). Continuous and categorical
variables were compared using Kruskal−Wallis and χ2 tests, respectively.
Abbreviations: COVID‐19, coronavirus disease‐2019; L, liter; mmol, millimole; n, frequency; STEMI, ST‐elevation myocardial infarction; %, percentage.

missingness are described in Supporting Information: Table 1S.

To assess the association of presentation period with survival in

Presentations of AMICS decreased by 44.5% when comparing the

our cohort, we performed logistic regression analyses (Table 3). In

pre‐ to the during COVID‐19 period (Supporting Information:

adjusted logistic regression models, COVID‐19 time period did not

Figure 1S).

significantly associate with survival to discharge (odds ratio [OR]:

Quality metrics of in‐hospital times were compared between the

1.09, 95% confidence interval [CI]: 0.54−2.19, p = 0.81), or with

two groups (Table 2). Door to balloon (90 vs. 88 min, p = 0.38), door

survival at 1‐month (OR: 0.82, 95% CI: 0.42−1.61, p = 0.56). In

to support (88 vs. 78 min, p = 0.13), and onset of shock to support (74

sensitivity analysis, repeating the analysis above using the date of

vs. 62 min, p = 0.15) times were not significantly different when

first COVID‐19 diagnosis in the United States as the start date for the

comparing those who presented before those who presented during

during COVID‐19 group yielded no significant differences in quality

the pandemic.

metrics or outcomes (Supporting Information: Tables 2S and 3S).

Characteristics of AMICS admissions are also described (Table 2).
Rates of cardiac arrest before arrival in the cardiac catheterization lab
were not significantly different between the two groups. Rates of

4 |
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treatment with hypothermia were also similar. There was a trend
toward a decrease in presentation as a transfer from another hospital

In this national analysis of 406 patients from 80 US hospitals, we

during COVID‐19 compared to prior, which was statistically

show a 44.5% decrease in AMICS presentations during COVID‐19

nonsignificant (16.7% vs. 27.8%, p = 0.07). Presentations with STEMI

when compared to similar months the year prior. Hospital quality

were increased during the COVID‐19 period (95.0% vs. 80.0%,

metrics, including door to support, onset of shock to support, and

p = 0.005). Presence of shock on admission (67.4% vs. 60.0%,

door to balloon times, were similar among those presenting pre‐ and

p = 0.24) and median serum lactate before mechanical circulatory

during the pandemic. In adjusted models, COVID‐19 time period did

support with Impella placement (3.7 mmol/L [2.0–6.7] vs. 2.5

not associate with patient outcomes, including survival to discharge

[2.0–5.1] during COVID‐19; p = 0.17) were not statistically signifi-

and survival at 1 month. Of note, we did find a significantly higher

cantly different pre‐COVID‐19 compared to during the COVID‐19

proportion of patients presenting with STEMI during the COVID‐19

pandemic.

pandemic. Overall, our findings suggest that the care of patients
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p Value

Adjustedb
OR [95% CI]

p Value

1.17 [0.63−2.16]

0.63

1.09 [0.54−2.19]

0.81

0.98 [0.54−1.77]

0.94

0.82 [0.42−1.61]

0.56

Outcome

Unadjusted
OR [95% CI]

Survival to discharge
Survival at 1 month

a

ET AL.

T A B L E 3 Association of period (pre‐
COVID‐19 vs. during COVID‐19) with
survival of patients enrolled in NCSI
presenting with acute myocardial
infarction and cardiogenic shock

Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease‐2019; OR, odds ratio.
a

Logistic regression models compared during the COVID‐19 period to pre‐COVID‐19 (reference).

b

Regression models adjusted for age, sex, race, and medical comorbidities (history of diabetes,
transient ischemic attack/cerebrovascular accident, end‐stage renal disease, chronic kidney disease,
left ventricular ejection fraction <50%, prior coronary artery bypass grafting, prior percutaneous
coronary intervention, prior myocardial infarction).

presenting with AMICS remained robust among hospitals taking part
in the NCSI during the COVID‐19 pandemic.

One possible explanation for the higher percentage of cases
presenting with STEMI in the NCSI cohort during the COVID‐19

To our knowledge, this is the first analysis of AMICS epidemiol-

pandemic is that some patients with acute coronary syndrome may

ogy and mortality outcomes during the COVID‐19 pandemic in the

have delayed presenting to the hospital until symptoms further

US population. One publication of AMICS incidence during the

progressed. This possibility is consistent with a single center study

COVID‐19 era using Danish data has been previously reported.20

that reported time from symptoms to hospital admission was

These authors found no significant difference in the incidence of

significantly prolonged in patients with STEMI during COVID‐19

AMICS from a larger patient population (>13,000 patients) studied

compared to a historical cohort.27 Although a higher percentage of

for a shorter period of time (during COVID‐19 group ending in May

patients in the NCSI cohort presented with STEMI during COVID‐19,

20

2020).

In our national US cohort, we demonstrate decreased

we did not observe additional signs of decompensation by other

presentations for AMICS, which is congruent with prior data in the

metrics such as the presence of shock on admission or higher serum

United States demonstrating decreased presentations for acute

lactate before mechanical support.

coronary syndrome.1–3 Decreased presentations and delayed pre-

Although, to our knowledge, Lauridsen et al.20 and our

sentations of STEMI have also been suspected globally by physicians,

manuscript are the only two reports examining AMICS, other studies

with the majority surveyed reporting >40% reduction in STEMI

have examined the incidence, characteristics, and outcomes of acute

presentations.8

myocardial infarction during the COVID‐19 pandemic. Presentations,

Similar to the results from the Denmark national registries,

outcomes, and management of acute coronary syndrome (ACS) have

we found no significant difference in hospital process measures

differed across the globe during the pandemic. At a single center in

or in‐hospital mortality.20 As the underlying biology and natural

Wuhan, China, Huang et al.12 found a fourfold increase in all‐cause

progression of coronary artery disease to acute myocardial

mortality in patients presenting with STEMI in the first two months of

infarction would not be expected to change significantly in the

the COVID‐19 pandemic compared to the prior year. These patients

period of study by our group and our Danish colleagues, it is

presenting with STEMI had increased time from symptoms to

possible that our observed decrease in AMICS presentations

intervention, as well as a relative increase in emergency thrombolysis

relates to differences in behavioral decisions about seeking

and decrease in primary PCI.12 A tertiary medical center in Germany

healthcare. The significantly higher number of COVID‐19 cases

also found increased complications and mortality among patients

present in the United States (10 million cases, 3.11% population

presenting with acute myocardial infarction during the early stage of

infected), when compared to Denmark (57 thousand cases, 0.99%

the COVID‐19 pandemic.14

population infected) during the period studied, likely had an

Data from other countries have differed from the findings

influence on patient decisions to present for medical care.21–23 In

reported from China and Germany. In a cohort of more than 30,000

a behavioral study surveying 2201 adults across the United

patients presenting with STEMI across 44 healthcare centers in

States from April 18 to April 20, 2020, 29% of US adults surveyed

England, no significant difference was found for multivariable‐

reported actively delaying or avoiding medical care due to

adjusted in‐hospital death or major adverse cardiovascular events

concerns for contracting COVID‐19. 24 This sentiment appears

despite significantly less use of PCI and longer door‐to‐balloon times

to have sustained as 12.0% of 4975 US adults surveyed by the

in patients who did undergo PCI.11 Interestingly, a regional

Center for Disease Control from June 24 to June 30, 2020,

US analysis of acute myocardial infarction before and during the

reported to have delayed or avoided urgent or emergency

COVID‐19 pandemic found no differences in treatment approach,

medical care.

25

Delays in US adults seeking medical care during

but did find significantly increased observed deaths compared to

our COVID‐19 pandemic period of study has been similarly

expected deaths for patients presenting with STEMI.2 These

reported in multiple additional publications and surveys such as

publications reporting data from three different continents suggest

the US Census “Household Pulse Survey.” 26

that at least in some populations and health systems, broad trends
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toward worse hospital quality measures, and in some instances,

However, the NCSI does include a diverse array of medical

higher mortality burden were observed during the immediate phase

centers throughout the United States ranging from predomi-

of the COVID‐19 pandemic for acute coronary syndrome and its

nantly private to largely academic.

complications.
Considering noted trends toward worse process measures and
outcomes for acute coronary syndrome during the COVID‐19

5 |

CONCLUSIONS

pandemic, our study importantly notes no significant difference in
quality metrics for timeliness of care or mortality in AMICS. One

Among hospitals participating in the NCSI, patients presenting with

possible explanation of our findings may be the high‐fidelity use of

AMICS during the COVID‐19 pandemic received similar quality of

prespecified protocols for patients enrolled in NCSI. These protocols

care and experienced similar risk‐adjusted outcomes when compared

may have helped maintain quality of care in the setting of acute

with patients with AMICS presenting before the COVID‐19

cardiovascular disease such as AMICS, particularly during a prolonged

pandemic. These findings show that in NCSI centers with highly

systemically disruptive event such as the COVID‐19 pandemic.

protocolized management pathways, AMICS care has remained

Medical centers participating in NCSI by necessity had active review

robust during the COVID‐19 pandemic.

of their cardiac catheterization activation protocols, and a prespecified quality measure of the door to mechanical support time of less
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| Study limitations

Our study is limited by its retrospective, observational nature.

2.

We can only evaluate associations and not causality. Though we
adjusted for medical comorbidities in our regression models, the
potential for residual confounding remains. COVID‐19 infection

3.

status at the time of presentation with AMICS or following
presentation is not available in NCSI, and so we are unable to
comment on how the care of AMICS patients differed between
those infected and not infected with COVID‐19. Our data

4.

come from sites enrolled in the NCSI and only applies to patients
who present with ACS and cardiogenic shock, and therefore may
not be readily generalizable to the broader US population.

5.
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